Autolus Historical Cash Flow
| AUTL Stock | USD 3.27 0.17 5.48% |
Analysis of Autolus Therapeutics cash flow over time is an excellent tool to project Autolus Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Depreciation of 4.3 M or Capital Expenditures of 9.5 M as it is a great indicator of Autolus Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Autolus Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Autolus Therapeutics is a good buy for the upcoming year.
Autolus |
About Autolus Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Autolus balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Autolus's non-liquid assets can be easily converted into cash.
Autolus Therapeutics Cash Flow Chart
Add Fundamental
Capital Expenditures
Capital Expenditures are funds used by Autolus Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Autolus Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Autolus Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Autolus Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.At this time, Autolus Therapeutics' Other Non Cash Items is quite stable compared to the past year.
| 2021 | 2022 | 2023 | 2024 (projected) | Capital Expenditures | 8.9M | 10.8M | 11.0M | 9.5M | Depreciation | 8.5M | 7.4M | 6.6M | 4.3M |
Autolus Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Autolus Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Autolus Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (6.1M) | (57.3M) | 156.6M | 72.1M | (142.4M) | (135.3M) | |
| Total Cashflows From Investing Activities | (18.7M) | (14.7M) | (8.9M) | (10.8M) | (9.8M) | (10.2M) | |
| Depreciation | 4.6M | 5.7M | 8.5M | 7.4M | 6.6M | 4.3M | |
| Capital Expenditures | 18.7M | 14.7M | 8.9M | 10.8M | 11.0M | 9.5M | |
| Total Cash From Operating Activities | (101.5M) | (117.8M) | (117.9M) | (112.3M) | (145.6M) | (138.3M) | |
| Change To Operating Activities | (14.8M) | (29K) | 6.0M | 3.9M | 4.5M | 4.8M | |
| Net Income | (123.8M) | (142.1M) | (142.1M) | (148.8M) | (208.4M) | (198.0M) | |
| Total Cash From Financing Activities | 108.9M | 74.4M | 284.1M | 223.6M | (883K) | (838.9K) | |
| End Period Cash Flow | 211.4M | 154.1M | 310.7M | 382.8M | 240.3M | 203.9M | |
| Change To Netincome | 34.0M | 17.3M | 11.6M | 25.1M | 28.9M | 30.4M | |
| Change To Liabilities | (1.5M) | 1.4M | (1.8M) | 22K | 19.8K | 18.8K | |
| Free Cash Flow | (120.2M) | (132.4M) | (126.7M) | (123.1M) | (156.6M) | (148.7M) | |
| Change In Working Capital | (16.2M) | 1.4M | 4.1M | 4.0M | 292K | 295.6K | |
| Begin Period Cash Flow | 217.6M | 211.4M | 154.1M | 310.7M | 382.8M | 401.9M | |
| Other Cashflows From Financing Activities | 108.9M | (5.3M) | 38.2M | 59.8M | (883K) | (838.9K) | |
| Other Non Cash Items | 4.1M | (1.5M) | 1.8M | 13.4M | 45.7M | 48.0M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.22) | Revenue Per Share 0.043 | Quarterly Revenue Growth 6.81 | Return On Assets (0.22) | Return On Equity (0.82) |
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.